Fig. 1 | British Journal of Cancer

Fig. 1

From: Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

Fig. 1

Ilorasertib plasma concentration-time profiles (day 1 and 15). Mean (+s.d.) ilorasertib plasma concentration-time profiles (linear scale) following oral administration in Arm I (a), Arm II (b), and i.v. infusion in Arm III (c). aIn the 340-mg dose cohort, two of three patients had high ilorasertib exposure at day 1; however, there were no available data for these two patients at day 15. BID twice daily; i.v. intravenous; QD once daily

Back to article page